IP Library Granted Patent US 12,370,230
Granted Patent B2
US 12,370,230 · App. 17/502,531 · Granted Jul 29, 2025

Hemp and PEA formulation and its use

Inventors: Elnaz Karimian Azari (Aliso Viejo, CA); Annalouise O'Connor (Aliso Viejo, CA); Nikhat Contractor (Aliso Viejo, CA)
Assignee: METAGENICS LLC
A61K36/185A61K31/015A61K31/05A61K31/164A61P25/04A61P39/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,370,230
App. No.
17/502,531
Granted
Jul 29, 2025
Kind
B2
Abstract

This disclosure provides a composition comprising a synergistic mixture of hemp oil extract and palmitoylethanolamide (PEA), and a method for suppressing inflammatory and neuropathic pain by administering the composition to a subject. The anti-inflammatory and antinociceptive properties of the composition may be attributed by the entourage effect on the endocannabinoid system. Increasing the levels of endocannabinoids by inhibiting either their degradation or transport from the extracellular space back into the cells is a potential therapeutic target for managing these diseases.

Claims (63)

1. A composition for administration to a subject, the composition comprising a synergistic combination of:

palmitoylethanolamide (PEA); and

a hemp oil comprising a broad-spectrum hemp extract obtained from aerial parts of industrial hemp plants comprising a phytocannabinoid component comprising cannabidiol (CBD);

wherein the PEA and the hemp oil are present in the composition in a weight ratio (wt./wt.) of from about 1.2:1 to about 4.5:1 (PEA:hemp oil), and

wherein the composition is formulated for oral administration to the subject.

2. The composition of claim 1 , wherein the combination of the PEA and the hemp oil is present in the composition in an amount effective to, upon administration of a serving of the composition to a subject:

(i) regulate tissue endocannabinoid levels;

(ii) inhibit or reduce nociception;

(iii) induce or increase analgesia;

(iv) inhibit or reduce inflammation;

(v) improve a self-reported quality of life of the subject; or

(vi) any combination of (i)-(v); of the subject.

3. The composition of claim 1 , wherein the composition has a serving size with a total weight of from about 300 to about 1800 mg, and wherein the composition comprises:

(i) from about 300 to about 700 mg, optionally from about 300 to about 600 mg, of the PEA;

(ii) from about 70 to about 500 mg of the hemp oil; or

(iii) both (i) and (ii); in a serving of the composition.

4. The composition of claim 1 , wherein the composition comprises:

(i) from about 300 to about 600 mg of the PEA; and

(ii) from about 70 to about 500 mg of the hemp oil.

5. The composition of claim 3 , wherein the PEA is present in an amount of from about 38 to about 43 weight percent (wt. %) and the hemp oil is present in amount of from about 31 to about 35 wt. %, each based on the total weight of the serving of the composition.

6. The composition of claim 1 , wherein the hemp oil comprises

a terpene component comprising at least one terpene.

7. The composition of claim 1 , wherein the phytocannabinoid component:

also comprises cannabigerol (CBG); and

is present in an amount of at least 15 mg in a serving of the composition.

8. The composition of claim 1 , wherein the composition comprises the PEA and the phytocannabinoid component (PCC) of the hemp oil in a weight ratio of from about 50:1 to about 30:1, optionally of about 40:1 (PEA:PCC).

9. The composition of claim 8 , wherein the composition comprises the PEA and the PCC of the hemp oil in a weight ratio of about 40:1 (PEA:PCC).

10. The composition of claim 6 , wherein the terpene component:

(i) comprises β-caryophyllene (BCP);

(ii) is present in an amount of at least 3 mg in a serving of the composition; or

(iii) both (i) and (ii).

11. The composition of claim 1 , wherein the composition is adapted for administration to the subject in a dosage form comprising a softgel or capsule shell encapsulating a dose of the combination of the PEA and the hemp oil, and wherein a serving of the composition comprises at least one dose, optionally at least two doses, of the softgel or capsule shell encapsulated combination.

12. The composition of claim 11 , wherein the serving of the composition comprises at least two doses of the softgel or capsule shell encapsulated combination.

13. A method of ameliorating a condition of a subject comprising administering to the subject an effective amount of the composition of claim 1 , wherein the condition of the subject is associated with:

(i) pain;

(ii) inflammation;

(iii) stress;

(iv) neuropathy; or

(v) any combination of (i)-(iv); in the subject.

14. The method of claim 13 , wherein the composition is administered to the subject in an amount effective to:

(i) modulate the endocannabinoid system;

(ii) regulate tissue endocannabinoid levels;

(iii) inhibit or reduce nociception;

(iv) induce or increase analgesia;

(v) inhibit or reduce inflammation;

(vi) improve self-reported quality of life; or

(vii) any combination of (i)-(vi); of the subject.

15. The method of claim 13 , wherein the method comprises administering the composition to the subject in an amount effective to modulate the endocannabinoid system of the subject, wherein modulating the endocannabinoid system of the subject comprises:

(i) inhibiting the activity of fatty acid amide hydrolase (FAAH);

(ii) reducing the expression of fatty acid amide hydrolase (FAAH); or

(iii) both (i) and (ii); in the subject.

16. The method of claim 13 , wherein the method comprises administering the composition to the subject in an amount effective to regulate tissue endocannabinoid levels of the subject, and wherein regulating tissue endocannabinoid levels comprises:

(i) increasing levels of anandamide (AEA);

(ii) increasing levels of 2-arachidonolyglycerol (2-AG); or

(iii) both (i) and (ii); in tissue of the subject.

17. The method of claim 13 , wherein the composition is provided in a dosage form comprising a softgel or capsule shell encapsulating a dose of the combination comprising about 300 mg of the PEA and from about 70 to about 250 mg of the hemp oil, and wherein the method comprises orally administering at least one, optionally at least two, of the softgel or capsule shell encapsulated combination to the subject per day for at least two consecutive days.

18. The method of claim 17 , wherein the method comprises orally administering at least two of the softgel or capsule shell encapsulated combination to the subject per day for at least two consecutive days.

19. The composition of claim 1 , comprising:

about 300 mg of the PEA;

about 70 mg of the hemp oil; and

about 3.75 mg of a blend of black pepper fruit oil and clove bud oil;

wherein the composition is adapted for administration to the subject in a dosage form comprising a softgel encapsulating a dose of a combination of the PEA, the hemp oil, and the blend of black pepper fruit oil and clove bud oil, and

wherein a serving of the composition comprises at least one dose, optionally at least two doses, of the softgel.

Assignments (3)
SECURITY INTEREST Recorded Dec 22, 2025
From: METAGENICS LLC
To: WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT
Reel/Frame 073293/0381 →
CHANGE OF NAME Recorded Feb 16, 2024
From: METAGENICS, INC.
To: METAGENICS LLC
Reel/Frame 066624/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2021
From: CONTRACTOR, NIKHAT; KARIMIAN AZARI, ELNAZ; O'CONNOR, ANNALOUISE
To: METAGENICS, INC.
Reel/Frame 057820/0325 →
Continuity (3)
Continuation In Part PCTUS2020028081 · Apr 14, 2020
Provisional Application 62834325 · Apr 15, 2019
Related Publication 20220031782A1 · Feb 3, 2022
References Cited (78)
US 20170224645A1 · Migliaccio et al. · 2017 [cited by applicant]
US 20200000765A1 · Borok · 2020 [cited by applicant]
US 20200289459A1 · Geiling et al. · 2020 [cited by applicant]
EP 3417846A1 · 2018 [cited by applicant]
WO 1994012466A1 · 1994 [cited by applicant]
WO 2015068052A2 · 2015 [cited by applicant]
WO 2016174661A1 · 2016 [cited by applicant]
WO 2018157202A1 · 2018 [cited by applicant]
WO 2019136351A1 · 2019 [cited by applicant]
Hesselink et al., Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series, 2012, J Pain Research, 5: 437-442. [cited by examiner]
International Search Report for PCT/US2020/028081 dated Aug. 3, 2020, 3 pages. [cited by applicant]
Cary Leizer BA, David Ribnicky PhD, Alexander Poulev PhD, Slavik Dushenkov PhD & Ilya Raskin PhD (2000) The Composition of Hemp Seed Oil and Its Potential as an Important Source of Nutrition, Journal of Nutraceuticals, … [cited by applicant]
Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J. Oct. 29, 2013;4(4):e0022. [cited by applicant]
Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. Jun. 2017;174(11):1349-1365. [cited by applicant]
Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. Jul. 1, 201… [cited by applicant]
Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. Oct. 2016;82(4):932-42. [cited by applicant]
Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, Di Marzo V. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its ac… [cited by applicant]
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. Aug. 2011;163(7):1344-64. [cited by applicant]
Di Marzo V, Piscitelli F. The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics. Oct. 2015;12(4):692-8. [cited by applicant]
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. Mar. … [cited by applicant]
Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, Hennig IM, Barrett DA, Constantinescu CS, Fischer PM, Gershkovich P. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administe… [cited by applicant]
Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, Lichtman AH. The Endogenous Cannabinoid System: a Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology. Ja… [cited by applicant]
National Research Council (US) Committee on Recognition and Alleviation of Pain in Laboratory Animals. Recognition and Alleviation of Pain in Laboratory Animals. Washington (DC): National Academies Press (US); 2009. PMI… [cited by applicant]
Medical Outcomes Study 36 Item SF, source: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html. [cited by applicant]
PROMIS-43 Profile, source: http://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-promis. [cited by applicant]
Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120. [cited by applicant]
Brief Pain Inventory, source: http://www.npcrc.org/files/news/briefpain_short.pdf. [cited by applicant]
American Pain Association Quality of Life Scale, source: https://www.theacpa.org/wp-content/uploads/2021/04/ACPA-Quality-of-Life-Scale.pdf. [cited by applicant]
Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, Calignano A, Muccioli GG, Orefice G. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a a… [cited by applicant]
Petrosino, Stefania et al., “2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation”, Frontiers in Pharmacology, May 2017, vol. 8, Article 308. [cited by applicant]
Gregory NS, Harris AL, Robinson CR, Dougherty PM, Fuchs PN, Sluka KA. An overview of animal models of pain: disease models and outcome measures. J Pain. Nov. 2013;14(11):1255-69. [cited by applicant]
Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. May 2001;92(1-2):147-57. [cited by applicant]
Andre, Christelle M et al. “Cannabis sativa: The Plant of the Thousand and One Molecules.” Frontiers in plant science vol. 7 19. Feb. 4, 2016. [cited by applicant]
Arruda, A. M. V. de ; Carregal, R. D. ; Ferreira, R. G., 2000. Apparent digestibility of diets with different starch levels for growing rabbits. Rev. Bras. Zootec., 29 (3): 769-775. [cited by applicant]
Askari VR, Shafiee-Nick R. The protective effects of beta-caryophyllene on LPS-induced primary microglia M1/M2 Imbalance: a mechanistic evaluation. Life Sci. Feb. 15, 2019;219:40-73. [cited by applicant]
Astarita G, Piomelli D. Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci. Sep. 15, 2009;877(26):2755-67. [cited by applicant]
Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol. Dec. 15, 2010;229(1-2):26-50. [cited by applicant]
Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1)… [cited by applicant]
Bennett GJ, Xie Yk. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. Apr. 1988;33(1):87-107. [cited by applicant]
Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). Jan. 2021;238(1):9-28. [cited by applicant]
Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. Jul. 16, 1998;394(6690):277-81. [cited by applicant]
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. Jul. 1994;53(1):55-63. [cited by applicant]
Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. Jul. 1, 2018;3(1):152-161. [cited by applicant]
Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an prally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. F… [cited by applicant]
Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, Giagnoni G. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the ra… [cited by applicant]
Curto-Reyes V, Kirschmann G, Pertin M, Drexler SK, Decosterd I, Suter MR. Neuropathic Pain Phenotype Does Not Involve the NLRP3 Inflammasome and Its End Product Interleukin-13 in the Mice Spared Nerve Injury Model. PLoS… [cited by applicant]
Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. Sep. 2004;3(9):771-84. [cited by applicant]
Duarte DB, Vasko MR, Fehrenbacher JC. Models of inflammation: carrageenan air pouch. Curr Protoc Pharmacol. Mar. 2012;Chapter 5:Unit5.6. [cited by applicant]
Dubový P, Brazda V, Klusáková I, Hradilová-Svíženská I. Bilateral elevation of interleukin-6 protein and mRNA in both lumbar and cervical dorsal root ganglia following unilateral chronic compression injury of the sciati… [cited by applicant]
Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. Dec. 1977;4(2):161-174. [cited by applicant]
Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G, Manzo I, Furiano A, Rizzo A, Imperatore R, Iannotti FA, D'Aniello E, Piscitelli F, Sca Rossi F, Cristino L, Di Marzo V, de Novellis V, Maione S. Palmitoyl… [cited by applicant]
Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res. Apr. 2016;62:107-28. [cited by applicant]
Franchi L, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13(4):325-332. Published Mar. 19, 2012. [cited by applicant]
Genaro K, Fabris D, Arantes ALF, Zuardi AW, Crippa JAS, Prado WA. Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats. Front Pharmacol. 2017;8:391. Published Jun. 21,… [cited by applicant]
Hammell, D C et al. “Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.” European journal of pain (London, England) vol. 20,6 (2016): 936-48. [cited by applicant]
LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharm… [cited by applicant]
Mabou Tagne A, Fotio Y, Lin L, Squire E, Ahmed F, Rashid TI, Karimian Azari E, Piomelli D. Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain.… [cited by applicant]
Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Pro… [cited by applicant]
Varrassi G et al. Towards an effective and safe treatment of inflammatory pain: a delphi-guided expert consensus. Adv Ther. 2019;36(10):2618-2637. [cited by applicant]
Schuel H et al. N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids. 2002; 121(1-2):211-227. [cited by applicant]
Lo Verme J et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19. [cited by applicant]
Tagne AM et al. Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain. Pharmacol Res. 2021:105545. [cited by applicant]
Coppola, M. et al., “Palmitoylethanolamide: From endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence”, Medical Hypotheses 81 (2013) 619-622. [cited by applicant]
Rahimi, A. et al., “Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice”, Neuroscience 290 (2015) 279-287. [cited by applicant]
Murakami K, Elmlund H, Kalisman N, Bushnell DA, Adams CM, Azubel M, Elmlund D, Levi-Kalisman Y, Liu X, Gibbons BJ, Levitt M, Kornberg RD. Architecture of an RNA polymerase II transcription pre-initiation complex. Scienc… [cited by applicant]
Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. Nov. 2010;16(11):1267-76. [cited by applicant]
Rock, E.M., Limebeer, C.L. & Parker, L.A. Effect of cannabidiolic acid and Δ9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. Psychopharmacology 235, 3259-3271 … [cited by applicant]
Russo, E., Guy, G. and Robson, P. (2007), Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis-Based Medicine. Chemistry & Biodiversity, 4: 1729-1743. [cited by applicant]
Sacerdote P, Niada S, Franchi S, Arrigoni E, Rossi A, Yenagi V, de Girolamo L, Panerai AE, Brini AT. Systemic administration of human adipose-derived stem cells reverts nociceptive hypersensitivity in an experimental mo… [cited by applicant]
Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. Nov. 2007; 10(11):1361-8. [cited by applicant]
Simão da Silva KAB, Paszcuk AF, Passos GF, Silva ES, Bento AF, Meotti FC, Calixto JB. Activation of cannabinoid receptors by the pentacyclic triterpene α,β-amyrin inhibits inflammatory and neuropathic persistent pain in… [cited by applicant]
Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg. Sep. 2007;105(3):838-47. [cited by applicant]
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. Mar.-Apr. 2014;64(2):83-103. [cited by applicant]
Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. Mar. 27, 2004;56(5):603-18. [cited by applicant]
Wise LE, Cannavacciuolo R, Cravatt BF, Martin BF, Lichtman AH. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology. Jan. 2008;54(1):181-8. [cited by applicant]
Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, Xu Y, Zhang L. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J Exp Med. Jun. 4, 2012;209(6):11… [cited by applicant]
Zhu YF, Linher-Melville K, Niazmand MJ, Sharma M, Shahid A, Zhu KL, Parzei N, Sidhu J, Haj C, Mechoulam R, Singh G. An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical mode… [cited by applicant]
Lin L, Yang H, Jones PJ. Quantitative analysis of multiple fatty acid ethanolamides using ultra-performance liquid chromatography-tandem mass spectrometry. Prostaglandins Leukot Essent Fatty Acids. Dec. 2012;87(6):189-9… [cited by applicant]